Hangzhou, China
Research view
Lung cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- EGFR 300
- PD-L1 162
- PD-1 156
- KRAS 98
- ALK 72
- TP53 10
- HER2 63
- MET 43
- PI3K 1
- STAT3 0
- AKT 2
- ROS1 27
- mTOR 0
- VEGF 23
- BRAF 9
- RET 9
- NRF2 1
- MAPK 1
- ERK 0
- STING 0
- STK11 7
- YAP 1
- DLL3 27
- CTLA-4 15
- RAS 15
- CTNNB1 0
- TROP2 13
- JAK 1
- HIF-1 1
- AMPK 0
- PARP 2
- KEAP1 5
- JNK 0
- MYC 1
- B7-H3 14
- GPX4 0
- HER3 11
- PTEN 4
- MEK 1
- TIGIT 6
- FGFR 3
- IL-6 1
- PPAR 0
- EZH2 2
- HDAC 0
- PRMT5 7
- FAK 0
- COX-2 0
- HMGB1 0
- NTRK 5
- AXL 3
- BCL-2 0
- CDK4/6 4
- CXCR4 1
- CD47 1
- METTL3 0
- NLRP3 0
- SHP2 0
- HSP90 0
- MDM2 1
EU-13 is a filter, not a ranking: it only narrows the list.
Baltimore, United States
University College London · London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Br J Gen Pract, Mar 2026Prediagnostic primary care consultations and imaging in emergency-diagnosed versus referred patients with lung cancer: a population-based linked data study.
Heidelberg, Germany
New York, United States
Chapel Hill, United States
Imperial College London · London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Int Immunopharmacol, Jan 2026MiR-146a-armed exosomes reverse immunosuppressive networks in NSCLC by dual-targeting of MYD88/STAT3 and PD-L1 axes.
Soochow University · Suzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Biochem Pharmacol, Jan 2026Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies.
Toronto, Canada
Heidelberg, Germany
Aurora, United States
Munich, Germany
Lausanne, Switzerland
Affiliated Hospital of Southwest Medical University · Luzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · J Nucl Med, Apr 2026[177Lu]Lu-DOTATATE and [177Lu]Lu-DOTA-IBA Cocktail Therapy for Metastatic Small Cell Lung Cancer: Possible Applications in Clinical Practice.
Pok Fu Lam, Hong Kong
Tokyo, Japan
Rome, Italy
Chongqing, China
18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
“Revisions to eligibility/design being made prior to enrollment of first participants.”Registry text, quoted unchanged. Source
Terminated
“This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source
Terminated
“The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source
Terminated
“Operational challenges”Registry text, quoted unchanged. Source
Suspended
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
“Administrative”Registry text, quoted unchanged. Source
Terminated
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
“The study was terminated prematurely due to insufficient patient recruitment”Registry text, quoted unchanged. Source
Terminated
“sponsor decision (not for safety)”Registry text, quoted unchanged. Source
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
“Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source
Terminated
“EF-50/LUNAR-4 was terminated because available real-world data are expected to enable Novocure to achieve the study objectives without an interventional clinical study. Termination was not due to safety concerns.”Registry text, quoted unchanged. Source
Suspended
“Discussion under way on how to continue/restart the study in view of slow recruitment rate.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 145
- Organoids 47
- Mendelian Randomization Analysis 66
- CRISPR-Cas Systems 43
- Gene Expression Profiling 314
- Sequence Analysis, RNA 43
- Whole Genome Sequencing 13
- Exome Sequencing 18
- Proteomics 133
- Metabolomics 67
- Mass Spectrometry 25
- Flow Cytometry 73
- Immunohistochemistry 191
- Liquid Biopsy 76
- Circulating Tumor DNA 83
- Xenograft Model Antitumor Assays 616
- Positron-Emission Tomography 70
- Magnetic Resonance Imaging 115
- Machine Learning 290
- Deep Learning 210
- Cohort Studies 289
- Genome-Wide Association Study 75
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.